%0 Journal Article
%T Tuberculosis treatment without rifampin in kidney/kidney-pancreas transplantation: A case series report.
%A Radisic MV
%A Pujato NR
%A Bravo PM
%A Del Grosso RC
%A Hunter M
%A Beltramino S
%A Linares González L
%A Cornet ML
%A Del Carmen Rial M
%A Franzini RL
%A Dotta AC
%A León LR
%A Walther J
%A Uva PD
%A Werber G
%J Transpl Infect Dis
%V 24
%N 6
%D Dec 2022
%M 36515463
暂无%R 10.1111/tid.13949
%X <B>BACKGROUND: </B>The best approach to tuberculosis (TB) treatment in transplanted patients is still unknown. Current guidelines are based on evidence either extrapolated from other populations or observational. Rifampin-containing regimens have strong pharmacokinetic interactions with immunosuppressive regimens, with high rates of organ dysfunction and ∼20% mortality. This report describes the results obtained using non-rifampin-containing regimens to treat confirmed TB in adult patients with kidney/kidney-pancreas transplantation.<BR><B>METHODS: </B>Retrospective data analysis from confirmed TB cases in adult kidney/kidney-pancreas transplant recipients (2006-2019), treated "de novo" with non-rifampin-containing regimens.<BR><B>RESULTS: </B>Fifty-seven patients had confirmed TB. Thirty patients were treated "de novo" with non-rifampin-containing regimens. These patients' mean age was 49.24 (±11.50) years. Induction immunosuppression was used in 22 patients. Maintenance immunosuppression was tacrolimus-mycophenolate-steroids in 13 (43%), sirolimus-mycophenolate-steroids in 6 (20%), and other immunosuppressive regimens in 11 (36%). Belatacept was used in four patients. TB localizations: pulmonary 43%; disseminated 23%; extrapulmonary 33%. Twenty-seven (90%) patients completed treatment with isoniazid, ethambutol, and levofloxacin (12 months, 23; 9 months, 3; 6 months, 1); 12 of these patients also received pyrazinamide for the first 2 months and were cured with functioning grafts. One patient (3%) lost the graft while on treatment. Two patients (7%) died while on TB treatment. Median (range) follow-up after completion of TB treatment was 32 (8-150) months. No TB relapses were observed.<BR><B>CONCLUSIONS: </B>Results with non-rifampin-containing TB treatments in this case series were better (in terms of mortality and graft dysfunction) than those previously described with rifampin-containing regimens in transplanted patients.